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A 35-year-old man presented to the Department of
Otolaryngology with progressive bilateral hearing loss, worse
on the right, over the past 12 years. Audiometry determined
the hearing loss to be mixed, both conductive and sensori-
neural. He had no otalgia, vertigo, or otorrhea. There was no
history of otologic surgery, noise exposure, or familial hearing
loss. He described remote minor head injury at age 4 years
that required stitches, and prior fractures, which generally
occurred during hockey matches, of his clavicle, fingers, a toe,
and the left tibia and fibula. He was not taking any regular
medications. Results of a general physical examination were
normal. Results of an otologic examination revealed tortuous
external auditory canals bilaterally but normal tympanic
membranes. High-resolution computed tomography of the
temporal bones was performed (Figures 1 and 2).
Diagnosis
Osteogenesis imperfecta (OI), type I.
Findings
High-resolution computed tomography of the temporal
bones (Figures 1 and 2) demonstrated extensive lucency of
the bony otic capsule around the cochlea, vestibule, and
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appeared normal, in particular, the stapes did not demon-
strate any footplate thickening. The external auditory canals,
mastoids, internal auditory canals, and vestibular aqueducts
were unremarkable.Discussion
OI is a genetic disease that affects collagen type I (COL1),
which leads to a range of manifestations dependent on the
mutation. The classic syndrome is progressive hearing loss,
blue sclera, and bone fragility. COL1 is composed of 2 alpha-
1 chains and 1 alpha-2 chain, in which each third residue is
a glycine amino acid, and elucidates the formation of the
triple helical structure [1]. OI results from mutations in
the COL1A1 or COL1A2 genes responsible for encoding the
alpha chains. Dependent on the mutation, different
phenotypes result and create subtypes I-IV [2e4]. Recently,
additional mutations were discovered in proteins associated
with the structural formation of COL1, which led to
identification of subtypes V-VII [5]. OI type I is most
common and is the least-severe subtype [5,6]. It results from
a frame shift mutation, premature stop codon, or splice site
mutation in COL1A1 or COL1A2, which leads to decreased
production of normal COL1 [3]. OI type I is autosomal
dominant and results in blue sclera, increased risk of bone
fractures, and progressive hearing loss in the second or third
decade of life. There may be dentinogenesis imperfecta.
Patients are of normal height, with no bone deformities [5].
OI type II is the most severe form and usually leads to
perinatal death. It results from mutations in the glycine
residue of the alpha chains, greatly disrupting the structural
stability of COL1. It is autosomal recessive and presents with
multiple bone fractures and deformities at birth, particularlyll rights reserved.
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may not present with blue sclera [5,6]. OI type III is the
most-severe subtype in those babies who survive the neonatal
period. It also is caused by a glycine residue mutation, which
leads to severe bone deformities, short stature, high bone
fragility, and possibly blue sclera, although this fades with
age. These patients are often wheelchair bound and may have
respiratory difficulties [6]. OI type IV is of intermediate
severity and usually represents the cohort of patients that do
not fit into subtypes I-III [6]. OI type V is autosomal
dominant, seen in 4%e5% of patients with OI. It shows no
dentinogenesis imperfecta or blue sclera but is characterized
by bone fragility and hypertrophic callous formation [5e7].
Type VI also shows no blue sclera or dentinogenesis
imperfecta but presents with bone fragility and deformity. It
is autosomal recessive, with negative screening results in
assays for COL1 mutations and does not respond to
bisphosphonate therapy [5,6]. Type VII is only observed in
an Aboriginal community in northern Que´bec and presents
with coxa vara and rhizomelia [5,6,8]. It is associated with
a mutation that leads to a change in expression of cartilage-
associated protein. In all subtypes of OI, DNA and fibroblast
screening can confirm a diagnosis, but a negative result does
not rule out the possibility of OI [5]. In our case, type I was
confirmed by genetic testing that demonstrated a COL1A1
mutation, a single nucleotide substitution that resulted in
a premature chain termination codon. There was no family
history of OI, so the patient’s mutation was likely sporadic,
although type I can have variable penetrance. The patient
presented with blue sclera, progressive hearing loss, and
a history of bone fractures but did not show any bone
deformities, short stature, or respiratory difficulties.
Bone fragility results from decreased bone mass and
deficient bone tissue. Demineralization of the temporal bone
can lead to hearing loss [9e11]. Differential diagnosis of this
appearance of the temporal bones includes otosyphilis,
otosclerosis, Paget disease, and rheumatoid arthritis [12].
Otosyphilis is only seen in advanced cases, and it manifests
as labyrinthitis, internal auditory canal gummatous lesions,
or inflammatory resorptive osteitis [13]. Paget disease is
unlikely in our patient, because this condition is expected at
an older age, and symptoms would be expected to manifest
in the axial skeleton before presentation of hearing loss.
Otosclerosis is the condition that most closely resembles OI
on computed tomography, but the extensiveness of
demineralization makes it less likely in this case [14]. The
otic capsule lucency in otosclerosis is usually only around
the cochlea and at the cochlear promontory (fissula ante
fenestram), with relative sparing of the semicircular canals
[14]. Rheumatoid arthritis can occasionally show temporal
bone erosions.Figure 1. Axial computed tomography images of the temporal bones at the
level of the cochlea (AeC), lateral semicircular canals and vestibule (D),
posterior semicircular canals (E), and superior semicircular canal (F). There
is extensive bony lucency in the otic capsule that surrounds the cochlea,
vestibule, and semicircular canals.
Figure 2. Coronal computed tomography re-formations of the temporal
bones at the level of the cochlea (A), vestibule and oval window (B), and
semicircular canals (C). There is extensive bony lucency in the otic capsule
that surrounds the cochlea, vestibule, and semicircular canals.
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provide some symptom relief and potentially improve
mobility and outcome. For mobility problems, rehabilitation,
physiotherapy, and orthopaedic surgery are important
treatments. Bisphosphonates, specifically pamidronate, have
been used with success. These act as antiresorptive agents,
disrupting the mevalonate pathway in cholesterol
biosynthesis in osteoclasts, thus inhibiting their function [5].
There have been reports of improved lower back pain,
increased performance on muscle-strength grip tests, and
improved metacarpal and iliac bone cortical thickness.Adverse effects include flu-like symptoms after the first
dosage, unexplained weight gain, and interference with bone
remodelling after surgery. Other pharmacologic agents that
have been investigated include growth hormone and
parathyroid hormone. Growth hormone actually increases
bone turnover, which is already accelerated in OI. This is not
desirable as a therapy by itself but may be useful in
combination with bisphosphonate therapy [5,6]. Parathyroid
hormone has been shown to cause osteosarcoma in young
patients and thus has not been used as a viable treatment
option, especially in young children [5,6]. Bone marrow
stromal cells have been transplanted into patients with OI,
but, unfortunately, the clinical benefits were minimal.
Current research is focusing on gene therapy ideally to turn
off the mutant allele and find a way to express the desired
wild type allele [5,6].
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